RT期刊文章SR电子T1 anti-LGI1评价癫痫治疗,anti-NMDAR,和anti-GABABbR脑炎(S11.008)摩根富林明神经学神经学乔FD Lippincott Williams &威尔金斯SP S11.008 VO 92 15补充A1 Marienke 首页De Bruijn A1艾格尼丝·Sonderen A1玛莲Van Coevorden-Hameete A1安娜Bastiaansen A1马可Schreurs A1 Rob Rouhl A1齐斯·范Donselaar A1 Marian Majoie A1 Rinze Neuteboom A1彼得Sillevis Smitt A1罗兰Thijs A1 Maarten Titulaer年2019 UL //www.ez-admanager.com/content/92/15_Supplement/S11.008.abstract AB目的:评估响应的癫痫患者的免疫治疗和抗癫痫药物(aed) anti-leucine-rich glioma-inactivated 1 (LGI1) anti-N-Methyl-D-Aspartate受体(NMDAR)和anti-Gamma-Aminobutyric-Acid-B受体(GABABR)脑炎,描述慢性癫痫的风险。背景:癫痫发作频繁发生自身免疫性脑炎(AIE)。发作通常似乎对aed,同时对免疫疗法的反应是很好的。然而,没收自由并不总是实现在使用免疫疗法和aed有时需要。然而,目前尚不清楚aed在这些患者是安全的,如果他们是有效的,aed应该优先。设计/方法:最近诊断为癫痫患者和anti-LGI1 anti-GABABR或anti-NMDAR脑炎是包含在这个全国性的队列研究。疾病医疗信息,类型的aed和免疫疗法使用,效果和副作用收集。结果措施:1)没收自由达到在使用aed,虽然使用免疫治疗,2)天没收自由从开始aed和免疫治疗,3)慢性癫痫的发展,和4)报道的副作用。结果:153年AIE病人(53 LGI1;75 NMDAR;25 GABABR), 72% (n = 110)有癫痫,89%达到夺取自由。至少53%达到夺取自由免疫治疗后不久,和14%达到夺取自由而只使用aed (p < 0.0001)。 Median time to seizure freedom from AEDs start was 59 days (IQR 27–160), and 28 days from start of immunotherapy (IQR 9–71, p<0.0001). Carbamazepine was more effective than levetiracetam in reducing seizures in anti-LGI1 encephalitis (p=0.031). Only one patient, of 86 surviving patients, developed chronic epilepsy.Conclusions: Seizure freedom is achieved faster and more frequently after immunotherapy than after AEDs in patients with anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. AEDs should be considered as add-on therapy, and similar to treatment of other encephalitis symptoms, immunotherapy is most crucial. Chronic epilepsy is rare in adequately treated AIE.Disclosure: Dr. De Bruijn has nothing to disclose. Dr. Van Sonderen has nothing to disclose. Dr. van Coevorden-Hameete has nothing to disclose. Dr. Bastiaansen has nothing to disclose. Dr. Schreurs has nothing to disclose. Dr. Rouhl has nothing to disclose. Dr. van Donselaar has nothing to disclose. Dr. Majoie has nothing to disclose. Dr. Neuteboom has nothing to disclose. Dr. Sillevis Smitt has nothing to disclose. Dr. Thijs has nothing to disclose. Dr. Titulaer has received research support from MedImmune LLC., Guidepoint LLC.

map